TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04363749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint
Description: the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint
Description: the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
Study: NCT04637126

Intervention type: OTHER
Intervention: Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography
Description: Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
Study: NCT02701231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency Rotating Magnetic Therapy System
Description: Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic anti-tumor therapy
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Systemic anti-tumor therapy
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-frequency Rotating Magnetic Therapy System
Description: Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
Study: NCT03071328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-M 200
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-M 200
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-M 200
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
Study: NCT03558555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intravenous saline
Study: NCT02823600

Intervention type: DEVICE
Group type: OTHER
Intervention: RetinaVue 100 camera
Description: Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
Study: NCT02537483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-120 Component A
Description: Comparator Product: IDP-120 Component A
Study: NCT06716762

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Open cyst excision and Roux-en-Y hepaticojejunostomy performed through a 10 cm incision

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy performed through small incisions with a laparoscope
Study: NCT02028754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Carboxymethylcellulose
Description: Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
Study: NCT01646307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study: NCT01950975

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood samples in EDTA tubes

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood samples in EDTA tubes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsies
Study: NCT04456530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aveed 750 MG in 3 ML IM Injection
Description: Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 3 ML IM Injection
Description: Participants in the Control Group will receive two IM normal saline injections 1 month apart.
Study: NCT03555916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX®, Allergan
Description: 50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Study: NCT05009654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-leucine
Study: NCT00190671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study: NCT02537483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-120 Component B
Description: Comparator Product: IDP-120 Component B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-120 Vehicle Gel
Description: Comparator Product: IDP-120 Vehicle Lotion
Study: NCT03757572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate dressings
Description: The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple gauze dressings
Description: The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried.
Study: NCT01724242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal DHEA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01828775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive early PCI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive delayed PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study: NCT04434677

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionation
Description: 3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultraHypofractionation
Description: 3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
Study: NCT01697969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2%
Study: NCT02190643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation counseling with adherence focus
Study: NCT00956215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant placebo
Description: 80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
Study: NCT03071328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-M 200
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
Study: NCT02190643

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation counseling without adherence focus
Study: NCT02087124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Different amounts of whey protein dissolved in 200 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Different amounts of whey protein dissolved in 200 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Different amounts of whey protein dissolved in 200 mL water.
Study: NCT05290324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
Study: NCT03282734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)
Description: Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home rehabilitation exercise
Description: Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
Study: NCT05089929

Intervention type: DEVICE
Intervention: Endoflip 2.0
Description: FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.

Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
Study: NCT03380533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
Study: NCT00503542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terazol or oral fluconazole for candidal vaginitis
Description: Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazol or oral fluconazole for candidal vaginitis
Description: Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
Study: NCT03380533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Oral Scheme
Description: Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
Study: NCT01561989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study: NCT03380533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Oral Scheme
Description: Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablet that the patient consumes every 8 hours during the first five days
Study: NCT03330782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
Study: NCT03515902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mouthguard
Description: mouthguard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mouthguard with desensitizing toothpaste
Description: mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
Study: NCT03828448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: - anti-CD 20 monoclonal antibody administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: - PI3K Delta Inhibitor oral daily dose
Study: NCT04693338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive ICP tasks
Study: NCT02037165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: BI 1026706 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: BI 1026706 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib hard capsule
Study: NCT03126357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette
Study: NCT01561989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03126357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product